<DOC>
	<DOCNO>NCT01487564</DOCNO>
	<brief_summary>The purpose study investigate pharmacokinetics OROS hydromorphone healthy adult Taiwanese participant oral administration single 16 mg dose .</brief_summary>
	<brief_title>Pharmacokinetic Profile OROS Hydromorphone Healthy Taiwanese Participants With Different Genotypes UGT2B7 Gene</brief_title>
	<detailed_description>This single-center , open-label ( people know identity intervention ) , single-dose study healthy adult Taiwanese participant . A minimum 6 participant identify UGT2B7 *2/*2 variant genotype 12 participant identify UGT2B7 *1/*1 wild type genotype include study . The study explore impact genetic polymorphism UGT2B7 gene ( occurrence variant gene ) pharmacokinetics ( drug absorb body , distribute within body , remove body time ) OROS hydromorphone . This study consist screen phase follow 5-day open-label treatment phase . During screen phase , blood sample collect genetic test confirm presence UGT2B7 gene . During study period , upon completion 12-hour overnight fast , participant receive single oral 16-mg dose OROS hydromorphone morning Day 1 . Blood sample collect 72 hour dose determination plasma hydromorphone hydromorphone 3-glucuronide concentration . The safety tolerability 16-mg OROS hydromorphone also assess . The total study duration participant approximately 33 day .</detailed_description>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>Participation DNA analysis confirm UGT2B7 genotype status Body mass index ( BMI ) 18 25 kg/mÂ² , inclusive body weight less 50 kg Participants must utilize medically acceptable method contraception throughout entire study period 1 month study complete Each participant receive naloxone challenge test opioid dependency screen . Only participant pass challenge test allow continue study History current clinically medical illness condition investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry urinalysis Clinically significant abnormal physical examination , vital sign 12 lead electrocardiogram ( ECG ) Use certain prescription nonprescription medication , consumption product may interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>OROS Hydromorphone</keyword>
	<keyword>Hydromorphone</keyword>
	<keyword>Taiwan</keyword>
	<keyword>UGT2B7 Gene</keyword>
</DOC>